Roxadustat + rHuEPO
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Anemia of Chronic Kidney Disease
Conditions
Anemia of Chronic Kidney Disease
Trial Timeline
Feb 22, 2021 → Oct 12, 2021
NCT ID
NCT04655027About Roxadustat + rHuEPO
Roxadustat + rHuEPO is a approved stage product being developed by AstraZeneca for Anemia of Chronic Kidney Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04655027. Target conditions include Anemia of Chronic Kidney Disease.
What happened to similar drugs?
20 of 20 similar drugs in Anemia of Chronic Kidney Disease were approved
Approved (20) Terminated (5) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04655027 | Approved | Completed |
Competing Products
20 competing products in Anemia of Chronic Kidney Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aranesp® | Amgen | Approved | 43 |
| KER-047 | Keros Therapeutics | Phase 2 | 17 |
| LY2787106 | Eli Lilly | Phase 1 | 29 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 40 |
| epoetin beta + placebo | Chugai Pharmaceutical | Phase 3 | 40 |
| recombinant human erythropoietin + recombinant human erythropoietin placebo | Chugai Pharmaceutical | Phase 3 | 40 |
| recombinant human erythropoietin + recombinant human erythropoietin | Chugai Pharmaceutical | Phase 3 | 40 |
| darbepoetin alfa | Amgen | Phase 3 | 40 |
| Prasugrel | Daiichi Sankyo | Phase 1 | 29 |
| Prasugrel + Placebo | Daiichi Sankyo | Phase 2 | 35 |
| roxadustat | Astellas Pharma | Phase 3 | 40 |
| roxadustat | Astellas Pharma | Phase 3 | 40 |
| Roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 40 |
| Alefacept | Astellas Pharma | Phase 1 | 21 |
| Roxadustat | Astellas Pharma | Phase 2 | 35 |
| roxadustat | Astellas Pharma | Phase 1 | 29 |
| Roxadustat + Placebo | Astellas Pharma | Phase 3 | 40 |
| Roxadustat | Astellas Pharma | Pre-clinical | 26 |
| Roxadustat + Epoetin Alfa | Astellas Pharma | Phase 3 | 40 |
| roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 40 |